Pomahope 4mg (Pomalidomide)

Description  of  Pomahope 4mg (Pomalidomide 4mg)

Pomahope 4mg (Pomalidomide 4mg)is a Natco pharma product which is endorsed by FDA, containing an active anti-cancer drug called Pomalidomide. Pomahope 4mg (Pomalidomide 4mg) is available as orally bioavailable thalidomide derivative with various therapeutic activities such as; Immuno modulatory Anti-angiogenesis Anti-neoplastic Pomahope 4mg (Pomalidomide 4mg)  is similar to thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment. This may leads to severe liver injury. Pomahope 4mg (Pomalidomide 4mg)is involved in the treatment for regression & unmanageable multiple myeloma. Pomahope 4mg (Pomalidomide 4mg)  is used in the patients who are failing to response for Lenalidomide treatment. Pomahope 4mg (Pomalidomide 4mg) is used in combination with dexamethasone.

INDICATIONS of  Pomahope 4mg (Pomalidomide 4mg)

The major therapeutic indication of Pomahope 4mg (Pomalidomide 4mg) is involved in the treatment of multiple myeloma.
This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomahope 4mg (Pomalidomide 4mg)
Pomahope 4mg (Pomalidomide 4mg) is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor.

MECHANISM OF ACTION  of  Pomahope 4mg (Pomalidomide 4mg)

Pomalidomide directly inhibits angiogenesis and myeloma cell growth. This dual effect is central to its activity in myeloma, rather than other pathways such as TNF alpha inhibition, since potent TNF inhibitors including rolipram and pentoxifylline do not inhibit myeloma cell growth or angiogenesis. Upregulation of interferon gamma, IL-2 and IL-10 as well as downregulation of IL-6 have been reported for pomalidomide. These changes may contribute to pomalidomide's anti-angiogenic and anti-myeloma activities.

 SIDE EFFECTS  of  Pomahope 4mg (Pomalidomide 4mg)

Commonly reported side effects of pomalidomide include: anemia, anxiety, confusion, dizziness, neuropathy, neutropenia, peripheral neuropathy, and thrombocytopenia. 

Other side effects include: acute myocardial infarction, cerebrovascular accident, and febrile neutropenia. See below for a comprehensive list of adverse effects.

PRECAUTIONS  of  Pomahope 4mg (Pomalidomide 4mg)

There are two major worsening condition may occur during the treatment using with Pomahope 4mg (Pomalidomide 4mg).

Embryo fetal damage

Pomahope 4mg (Pomalidomide 4mg)capsules are contraindicated to pregnancy period. During the treatment, patients avoid to becoming pregnant. Use effective contraceptives for preventing pregnancy during therapy.

Venous & arterial thromboembolism

Patient who are receiving Pomahope 4mg (Pomalidomide 4mg)capsules have chance of getting deep vein thrombosis, pulmonary embolism, myocardial infarction & stroke. This type of condition should be treated by initiating prophylactic anti-thrombotic drugs. The patients who are acquiring this condition then thromboprophylaxis should be provided

DRUG INTERACTION of  Pomahope 4mg (Pomalidomide 4mg)

Pomahope 4mg (Pomalidomide 4mg) metabolism is mediated by CYP1A2 & CYP3A4. The concomitant use of Pomahope 4mg (Pomalidomide 4mg)with CYP1A2 drugs like Fluoxamine causes elevation of Cmax & AUC of Pomahope 4mg (Pomalidomide 4mg)and concludes as increased concentration of Pomahope 4mg (Pomalidomide 4mg) leads to higher extent of adverse effects associated with Pomahope 4mg (Pomalidomide 4mg) In this condition, reduce the dose of Pomahope 4mg (Pomalidomide 4mg) and recommended.

DOSAGE of  Pomahope 4mg (Pomalidomide 4mg)

The prescribed dose of Pomahope in multiple myeloma is 4mg should be administered orally as once a day on day 1 to 21 of reciprocated 28-day cycles.
Pomahope 4mg (Pomalidomide 4mg) should be concomitant with dexamethasone.
Pomahope 4mg (Pomalidomide 4mg) Capsules should be taken with or without food.
During hematological toxicities:
Neutropenia:
ANC (absolute neutrophils count) <500/mcl: Postpone the Pomahope therapy and provide CBC weekly
ANC more than or equal to 500/mcl: Continue the Pomahope 3mg daily.
Thrombocytopenia:
Platelets count <25,000/mcL: postpone the Pomahope treatment & follow the CBC
>50,000/mcL: continue 3mg of Pomahope
Pomahope 4mg (Pomalidomide 4mg) with potent CYP1A2 inhibitor:
During this combination reduce the dose of Pomahope by 50%
In renal impairment:
Initial dose of Pomahope is 3mg
In hepatic impairment:
Mild to moderate condition, an initial dose of Pomahope is 3mg; in severe condition, the initial dose of Pomahope is 2mg.

STORAGE  of  Pomahope 4mg (Pomalidomide 4mg)

Pomahope 4mg (Pomalidomide 4mg) should be stored at room temperature of 20℃ to 25℃ Protect from light Kept in dry & cool place.

MISSED DOSE of  Pomahope 4mg (Pomalidomide 4mg)

Have the missed dose immediately before next dose duration
Next dose time arrived then left off the missed dose and follows regular schedule.
Avoid taking extra dose at same time.
Please consult the doctor for further details.